Department of Ophthalmology, Kawasaki Municipal Hospital, Kanagawa, Japan.
Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
Jpn J Ophthalmol. 2021 Jul;65(4):472-481. doi: 10.1007/s10384-021-00841-9. Epub 2021 May 20.
To describe the characteristics of Japanese patients with hydroxychloroquine (HCQ) retinopathy developing within 3 years of treatment outset.
Retrospective case series METHODS: Three patients with HCQ retinopathy developing within 3 years of treatment outset have been identified in Japan since HCQ became available in 2015. Their medical charts, containing optical coherence tomography (OCT), fundus autofluorescence imaging, and visual field tests, were reviewed.
The treatment durations and cumulative doses until onset were 29-36 months and 182-326 g, respectively. The first patient had possible pre-existing maculopathy, although the abnormalities were ambiguous. The second and third patients had impaired renal function. The patients did not complain of severe visual disturbance at diagnosis, but visual field loss and disruption of the outer retinal segments consisting of a parafoveal pattern in the first case and a pericentral pattern (localized, 8 or more degrees from the center of the fovea) in the second and third cases were clearly observed on OCT. Even after HCQ discontinuation, their retinopathy showed slight progression on the visual field tests and OCT images. A blood sample was obtained from 1 patient on the day after HCQ discontinuation, and the whole blood level of HCQ was measured using validated liquid chromatography-tandem mass spectrometry. The HCQ level 27 h after the last dose was high, at 2240 ng/mL (suggested threshold > 1733 ng/mL).
Ophthalmologic screening from the initiation of HCQ treatment detected 3 cases of HCQ retinopathy developing within 3 years of treatment outset, including a patient with a high blood level of HCQ.
描述羟氯喹(HCQ)视网膜病变在治疗开始后 3 年内发展的日本患者的特征。
回顾性病例系列
自 2015 年 HCQ 上市以来,在日本已发现 3 例 HCQ 视网膜病变在治疗开始后 3 年内发展的患者。回顾了他们的病历,包括光学相干断层扫描(OCT)、眼底自发荧光成像和视野检查。
治疗持续时间和累积剂量分别为 29-36 个月和 182-326g。第一个患者可能存在预先存在的黄斑病变,尽管异常不明确。第二和第三个患者的肾功能受损。患者在诊断时没有抱怨严重的视力障碍,但在第一个病例中观察到视野丧失和外视网膜段(呈旁中心模式)中断,在第二个和第三个病例中观察到黄斑区周围模式(局部,距黄斑中心 8 度以上),这些在 OCT 上清晰可见。即使在停止使用 HCQ 后,他们的视网膜病变在视野检查和 OCT 图像上仍有轻微进展。从 1 名患者在停止使用 HCQ 后的第二天获得了一份血样,并使用经过验证的液相色谱-串联质谱法测量了全血中的 HCQ 水平。末次给药后 27 小时的 HCQ 水平较高,为 2240ng/mL(建议阈值>1733ng/mL)。
从开始使用 HCQ 治疗开始进行眼科筛查,检测到 3 例在治疗开始后 3 年内发展的 HCQ 视网膜病变,包括 1 例患者的 HCQ 血药浓度较高。